Pharma AI Tracker

Innovent's 2025 ESG report describes an AI+NGS wet-dry closed-loop antibody discovery platform that has been applied to multiple internal projects, shortening the antibody screening cycle and improving the efficiency of discovering high-quality candidate molecules.

Innovent says it has developed an AI-driven de novo design closed-loop system dedicated to small protein drug development. The same report says the system enables intelligent iteration from target elucidation to molecular optimization and has demonstrated a magnitude-level improvement in hit rates and R&D iteration speed in internal projects.

During the reporting period, Innovent upgraded its learning platform, turning the original online training platform into iTalent, an AI-powered intelligent learning platform.

Innovent's 2025 ESG report says protective measures implemented in 2024 for the WeMol computing platform and AI intelligence repository were followed by a security baseline for the electronic lab notebook system covering the R&D computing environment.

Alnylam said it is partnering with Viz.ai to develop an AI-enabled ATTR-CM care pathway that combines an FDA-cleared Us2.ai echocardiography algorithm with electronic health record connectivity. The release says the related AWARE study will launch at five pilot health systems later in 2026 to generate real-world evidence.

Partners: Viz.ai

Merck KGaA's 2025 annual report says the company also uses AIDDISON, its generative-AI discovery platform, internally in the Healthcare business for early-stage drug discovery.

Merck KGaA's 2025 annual report says myGPT Suite, its internal generative AI platform, has more than 32,000 active users a month (over half the workforce) and more than 90% cost savings versus off-the-shelf options.

Merck KGaA's 2025 annual report says its smartfacturing playbook, including modular manufacturing, AI energy optimization and predictive maintenance, cuts time to market by up to 50% and uses around 20% less energy at reference sites.

Roche added 2,176 NVIDIA Blackwell GPUs on premises in the US and Europe, bringing its combined on-premise and cloud footprint to more than 3,500 GPUs, as the next phase of an NVIDIA collaboration begun in 2023.

Partners: NVIDIA

Roche and Genentech (gRED) run a Lab-in-the-Loop approach that connects biology and chemistry experiments with Roche's AI models, now enhanced with NVIDIA BioNeMo.

Partners: NVIDIA

Roche says digital twins of production lines, powered by NVIDIA Omniverse libraries, let engineers optimize processes and factory designs.

Partners: NVIDIA

Galderma's 2025 annual report says the year included a new Artificial Intelligence Steering Committee exploring advanced analytical methods on the Global Sensitive Skincare Faculty's epidemiological survey, described as the largest worldwide profiling study of sensitive skin, with more than 16,000 subjects.

Lilly's NVIDIA-built supercomputer for AI-driven research came online in early 2026 to support discovery and other scientific work.

Partners: NVIDIA

Shionogi said a generative-AI solution for drafting regulatory documents in drug development was built by combining its medical writers' knowledge and its data scientists' AI design work with Hitachi's generative-AI know-how. A proof of concept at the company confirmed about a 50% reduction in clinical study report preparation time and about a 20% reduction in protocol preparation time. The same release says Shionogi licensed the solution to Hitachi, which began offering it to pharmaceutical and healthcare companies in Japan in February 2026.

Partners: Hitachi

plai supplies predictions and what-if scenarios to the R&D governance meetings where molecule progression decisions are taken.

Partners: Aily Labs

Sanofi says it uses machine learning and AI across R&D, including for writing clinical study reports. No tool or metrics are named on the page.

AI and machine-learning algorithms inside Moderna's design and ordering platform that optimize mRNA sequences for manufacturability and quality.

Sobi's capital markets presentation says AI improves physician engagement and supports world-class field-force effectiveness.

Under its AI agenda, Sobi's capital markets presentation includes applying data and AI to optimize supply and reduce cost of goods sold.

Sobi's capital markets presentation lists generative-AI authoring of clinical study reports and Module 2 on a map of technology it describes as enabling faster development-cycle time.

On the same technology map, Sobi lists AI-driven disease pathway understanding.

On the same technology map, Sobi lists a literature finder that uses AI beside its real-world-data insights platform.

Sobi says Florio, its rare-disease patient platform, has evolved into a platform generating real-world insights at scale and was co-created with patients and healthcare professionals using design expertise, digital technology and AI.

AstraZeneca, alongside Astellas and BMS, agreed to use and share operational data with Evinova's AI-native trial platform (an AstraZeneca health-tech business) to get benchmarks and recommendations that speed trials.

Partners: Evinova

Genmab says it has expanded its scientific focus to use data science and AI to aid in the discovery of new targets and biomarkers and to bolster its precision medicine and translational laboratory capabilities.